Non-alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma

被引:0
|
作者
Antonio Cuadrado
Aitor Orive
Covadonga García-Suárez
Agustín Domínguez
Jose Carlos Fernández-Escalante
Javier Crespo
Fernando Pons-Romero
机构
来源
Obesity Surgery | 2005年 / 15卷
关键词
OBESITY; LIVER; STEATOSIS; HEPATOCELLULAR CARCINOMA; INSULIN RESISTANCE; DIABETES;
D O I
暂无
中图分类号
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is characterized by an excessive accumulation of fatty acids and triglycerides within the cytoplasm of the hepatocytes of non-alcohol users. The natural history varies according to the initial histological diagnosis. A current consideration is that cryptogenic cirrhosis may be representative of a late stage of non-alcoholic steatohepatitis (NASH), which has lost its features of necroinflammatory activity and steatosis in up to 80% of patients. Since NASH is able to progress to cirrhosis, hepatocellular carcinoma (HCC) development may be an end-stage of this disease. We report below two clinical cases of patients diagnosed with NASH who developed HCC. The relationship between NAFLD and HCC is reviewed.
引用
收藏
页码:442 / 446
页数:4
相关论文
共 50 条
  • [1] Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma
    Cuadrado, A
    Orive, A
    García-Suárez, C
    Domínguez, A
    Fernández-Escalante, JC
    Crespo, J
    Pons-Romero, F
    OBESITY SURGERY, 2005, 15 (03) : 442 - 446
  • [2] MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis (NASH)
    Al-Sharhan, Fatima
    Dohan, Anthony
    Barat, Maxime
    Feddal, Adlane
    Terris, Benoit
    Pol, Stanislas
    Mallet, Vincent
    Soyer, Philippe
    EUROPEAN JOURNAL OF RADIOLOGY, 2019, 119
  • [3] LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC STEATOHEPATITIS (NASH) COMPARED TO NON-NASH PATIENTS
    Sadler, Erin
    Mehta, Neil
    Bhat, Mamatha
    Ghanekar, Anand
    Greig, Paul
    Grant, David
    Yao, Francis
    Sapisochin, Gonzalo
    TRANSPLANT INTERNATIONAL, 2017, 30 : 93 - 93
  • [4] Non-Alcoholic Steatohepatitis (NASH) as a Risk Factor in Hepatocellular Carcinoma (HCC) Development
    Clark, Samantha
    Zuk, Eric
    Kim, Yestle
    Gish, Robert
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 563 - 563
  • [5] Non-alcoholic steatohepatitis (NASH)
    Michael F. Sorrell
    Sandeep Mukherjee
    Current Treatment Options in Gastroenterology, 1999, 2 (6) : 447 - 450
  • [6] Non-alcoholic Steatohepatitis (NASH) and alcoholic Steatohepatitis (ASH)
    Roeb, Elke
    DRUG RESEARCH, 2021, 71 : S16 - S18
  • [7] Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
    Rios, Rafael S.
    Zheng, Kenneth, I
    Zheng, Ming-Hua
    CHINESE MEDICAL JOURNAL, 2021, 134 (24) : 2911 - 2921
  • [8] Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
    Rafael S. Rios
    Kenneth I. Zheng
    Ming-Hua Zheng
    中华医学杂志英文版, 2021, 134 (24) : 2911 - 2921
  • [9] Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
    Shimada, M
    Hashimoto, E
    Taniai, M
    Hasegawa, K
    Okuda, H
    Hayashi, N
    Takasaki, K
    Ludwig, J
    JOURNAL OF HEPATOLOGY, 2002, 37 (01) : 154 - 160
  • [10] Outcomes of liver transplantation in non-alcoholic steatohepatitis (NASH) versus non-NASH associated hepatocellular carcinoma
    Rajendran, Luckshi
    Perez, Carla F. Murillo
    Ivanics, Tommy
    Claasen, Marco P. A. W.
    Hansen, Bettina E.
    Wallace, David
    Yoon, Peter D.
    Sapisochin, Gonzalo
    HPB, 2023, 25 (05) : 556 - 567